GlassScriptPhysician profile
Sergio A Roman
NPI 1154994796
$6,708.62
in general payments reported to CMS, 2019-2025
24 companies · $2,076 in 2025
The $2,076 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $330 · 2022: $718 · 2023: $1,120 · 2024: $2,464 · 2025: $2,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,660.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,175.83 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.36 | 2023-2025 | Jardiance |
| Amgen INC. | $638.33 | 2021-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $572.75 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $570.69 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $542.17 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $402.21 | 2024-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $369.64 | 2024-2025 | Barostim Neo System |
| Novo Nordisk INC | $309.15 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $283.13 | 2021-2025 | Nexletol |
| Pfizer INC. | $182.08 | 2023-2025 | |
| Astellas Pharma US INC | $154.89 | 2021-2022 | |
| Intuitive Surgical, INC. | $133.91 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $118.11 | 2022-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.75 | 2023-2024 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $87.22 | 2023-2025 | Watchman Flx, Bodyguardian |
| Kiniksa Pharmaceuticals International, Plc | $70.05 | 2024 | Arcalyst |
| Heartflow, INC. | $58.04 | 2024 | |
| Abiomed | $56.84 | 2024-2025 | Impella |
| Atricure, INC. | $46.26 | 2024 | |
| Sanofi-Aventis U.S. LLC | $36.10 | 2024 | |
| Alnylam Pharmaceuticals INC. | $32.59 | 2025 | Onpattro |
| Kowa Pharmaceuticals America, INC. | $25.75 | 2021 | |
| Lilly USA, LLC | $17.77 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.